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Abstract
Management of invasive aspergillosis in high-risk patients remains challenging. There is an increasing demand for novel therapeutic strat-
egies aimed at enhancing or restoring antifungal immunity in immunocompromised patients. In this regard, modulation of speciﬁc innate
immune functions and vaccination are promising immunotherapeutic strategies. Recent ﬁndings have also provided a compelling rationale
for assessment of the contribution of the individual genetic proﬁle to the immunotherapy outcome. Altogether, integration of immuno-
logical and genetic data may contribute to the optimization of therapeutic strategies exerting control over immune pathways, ultimately
improving the management of fungal infections in high-risk settings.
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Aspergillus fumigatus is a ubiquitous mould that can adapt to a
broad range of environmental conditions [1]. A. fumigatus can
cause a number of diseases, ranging from allergic to invasive,
life-threatening forms of infection, which are strictly deﬁned
by the immune status of the host. The more severe forms of
aspergillosis occur in speciﬁc clinical settings, such as patients
with haematological malignancies and prolonged and severe
neutropenia, or patients on corticosteroid therapy and
receiving solid organ or stem cell transplantation. The man-
agement of invasive aspergillosis in high-risk settings remains
challenging, owing to intrinsic or acquired antifungal resis-
tance, organ dysfunction preventing the use of particular
agents, and the deleterious effects of deregulated inﬂamma-
tion. Thus, there is an ever-increasing demand for novel
therapeutic strategies to enhance or restore critical immune
functions that may be applied to patients at high risk for fun-
gal infections [1].
This review will highlight the conceptual advances made
regarding the cellular and immunological mechanisms under-
lying the host–fungus interaction, and how this knowledge
may be exploited for the successful design of immunothera-
peutic interventions. The pathophysiological mechanisms
underlying susceptibility to invasive aspergillosis are high-
lighted, along with the awareness that the genetic make-up
of the host may also critically contribute to the risk of
acquiring this disease [2,3].
Immunology of Aspergillosis: From Innate
to Adaptive Immune Responses
In the absence of major immune deﬁciencies, humans are rel-
atively resistant to infection by A. fumigatus, owing to the
immunological inertia of resting conidia [4]. This also implies
that, for most healthy humans, innate immune mechanisms
are sufﬁcient to clear the organism. These include the physi-
cal barriers of the respiratory tract and the activation of cel-
lular (alveolar macrophages, dendritic cells (DCs), and
recruited neutrophils) and humoral (pentraxin (PTX)3 (see
below), complement, and cytokines) effector mechanisms of
innate immunity (reviewed in [1]). Germination, however,
exposes fungal-speciﬁc carbohydrates that serve as targets
for invariant, germline-encoded pattern recognition recep-
tors—such as Toll-like receptors (TLRs) and C-type lectin
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receptors—that are crucial for the initiation of innate and
adaptive T-helper (Th) immune responses [5]. Generation of
a dominant Th1 response is essentially required for the
expression of protective immunity to the fungus. Through
the production of the signature cytokine interferon (IFN)-c,
Th1 cells are instrumental in optimal microbicidal activity of
phagocytes. In contrast, allergic manifestations following inha-
lation of conidia, resulting from overzealous Th2 responses,
are classic examples of the pathogenic role of T-cell dysreac-
tivity in fungal diseases. However, a further degree of com-
plexity of cross-regulatory innate and adaptive Th pathways
lies beyond the dichotomous Th1/Th2 model. Recent insights
have suggested a role for Th17 cells, as a link between T-cell
inﬂammation and the granulocytic inﬂux observed in allergic
airway inﬂammation [5]. The Th17 pathway, playing an
inﬂammatory role previously attributed to uncontrolled Th1
cell reactivity, and regulatory T-cells (Tregs), which are capa-
ble of ﬁne-tuning protective antimicrobial immunity in order
to minimize harmful immune pathology, are now regarded as
integral components of the immune response to the fungus
(Fig. 1). The enzyme indoleamine-2,3-dioxygenase (IDO) and
kynurenines pivotally contribute to this delicate balance by
providing the host with immune mechanisms that are ade-
quate for protection without necessarily eliminating fungal
pathogens or causing an unacceptable level of tissue damage
(see below). Speciﬁc antibodies against A. fumigatus have also
been detected in patients suffering from invasive aspergillosis,
and their role in infection could be of interest. Indeed, a
glycoconjugate vaccine was found to efﬁciently immunize and
protect mice against the infection [6], suggesting a role for
antibody-mediated protection in aspergillosis.
Aspergillosis as an Example of an
Inﬂammatory Disease
Although the inﬂammatory response to fungi may serve to
limit infection, an overzealous or heightened inﬂammatory
response may contribute to pathogenicity. This conceptual
principle is best exempliﬁed by the occurrence of severe
fungal infections in patients with immunoreconstitution syn-
drome, an entity characterized by localized and systemic
FIG. 1. Immunotherapy in aspergillosis. The ﬁgure shows recent ﬁndings on the innate and adaptive immune responses to Aspergillus fumigatus
and the possible strategies for immune intervention. Most of these immunotherapies have only been evaluated in animal models of aspergillosis.
Abs, antibodies; CSF, colony-stimulating factor; EC, epithelial cell; IFN, interferon; IL, interleukin; Mø, macrophage; PMN, polymorphonuclear
neutrophil; PRR, pattern recognition receptor; PTX3, pentraxin 3; TGF, transforming growth factor; Th, T-helper; Treg, regulatory T-cell. See the
text for details.
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inﬂammatory reactions of varying degrees that have both
beneﬁcial and deleterious effects on the host [7]. Intriguingly,
immunoreconstitution syndrome responses are found after
rapid resolution of immunosuppression, indicating that inﬂam-
matory responses can result in quiescent or latent infections
manifesting as opportunistic mycoses. Thus, although host
immunity is crucial in eradicating infection, immunological
recovery can also be detrimental and may contribute to
worsening disease in opportunistic and non-opportunistic
infections [7]. The association of persistent inﬂammation with
intractable Aspergillus infection is common in non-neutropenic
patients after allogeneic hematopoietic stem cell transplanta-
tion and in the hyper-IgE syndrome, in which increased levels
of proinﬂammatory gene transcripts have been described [8].
Therefore, the status of innate host immunity may contribute
signiﬁcantly to the pattern of diseases associated with fungal
exposure. Corroborating these ﬁndings, recent studies have
highlight the role of sterile inﬂammation—i.e. (auto)inﬂam-
mation caused by endogenous ligands—as a pathogenic deter-
minant responsible for inﬂammation-driven pathology in
aspergillosis [9]. Most prominently, in patients with chronic
granulomatous disease (CGD), a hyperinﬂammatory pheno-
type and defective fungal—typically A. fumigatus—clearance
have long been known to occur. This condition is crucially
exempliﬁed by recent ﬁndings in CGD mice, in which an
intrinsic, genetically determined failure to control inﬂamma-
tion caused by sterile fungal components determines the ani-
mals’ inability to resolve an actual infection with A. fumigatus
[10]. These observations highlight the truly bipolar nature of
the inﬂammatory process in infection. Early inﬂammation pre-
vents or limits infection, but an uncontrolled response may
eventually oppose disease eradication. A main implication of
these ﬁndings is that, at least in speciﬁc clinical settings, it is
an exaggerated inﬂammatory response that probably compro-
mises a patient’s ability to eradicate infection, and not an
‘intrinsic’ susceptibility to infection that determines a state of
chronic or intractable disease.
Translating Immunity into Clinical
Perspectives
Colony-stimulating factors (CSFs), granulocyte transfusion,
and cytokines
CSFs and cytokines, mainly IFN-c, have been utilized in the
clinical management of fungal diseases [11]. CSFs and granu-
locyte transfusions are used to augment the number and the
function of circulating neutrophils in neutropenic patients.
Studies in vitro, studies in animal models and limited patient
data provide a rationale for adjunctive IFN-c for invasive
aspergillosis. The limited clinical experience to date shows a
possible beneﬁt of these cytokines, and further controlled
clinical trials are needed to validate their routine use in can-
cer patients and stem cell transplant recipients with invasive
fungal infections, who are likely to have a poor response to
antifungal drug therapy [12]. Pairing IFN-c with CSFs could
be an option in the setting of refractory fungal disease,
although clinical experience is anecdotal, and the efﬁcacy of
this approach is not established (reviewed in [13]). More-
over, the diverse effects of CSFs on the immune system and
types of immune response generated suggest an activity for
CSFs beyond their effects on haematopoiesis [14]. For
instance, granulocyte–macrophage CSF has recently been
shown to play a key role in human DCs for activation of
inﬂammatory Th1 and Th17 cells, and to serve a non-redun-
dant function in the initiation of autoimmune inﬂammation
[15]. Emerging evidence demonstrates the beneﬁts of granu-
locyte transfusions for treating infections in patients after
treatment with high-dose chemotherapy, particularly the che-
motherapy associated with conditioning for haematopoietic
stem cell transplantion. The increased interest in the use of
therapeutic granulocyte transfusion in recent years has
stemmed largely from improvements in donor mobilization
methods. However, the evidence for clinical efﬁcacy is lim-
ited to that of case reports and small series, and the results
are not uniform. Randomized controlled clinical trials are
needed to determine whether this therapy is useful in either
clearing infections or prolonging survival [16,17].
T-cell therapy
T-cell-mediated heterologous immunity to different patho-
gens is promising for the development of immunotherapeutic
strategies. Fungus-speciﬁc CD4+ Th1 immunity is an appeal-
ing strategy for antifungal therapy [18]. Recently, an immuno-
genic epitope of the A. fumigatus cell wall glucanase Crf1 was
reported to be capable of inducing major histocompatibility
complex class II restricted memory CD4+ Th1 cells that are
cross-reactive with Candida albicans [19]. These data illus-
trate the existence of T-cell-based cross-protection for the
distantly related clinically relevant fungal pathogens that may
foster the development of immunotherapeutic strategies.
More recently, the usefulness of Treg-based immunothera-
peutic approaches in allogeneic transplanted patients has also
been investigated. Early adoptive therapy with Tregs followed
by conventional T-cells was shown to favour immunological
reconstitution, besides preventing graft-versus-host disease
without weakening the graft-versus-leukaemia effect [20].
However, whether and how adoptive immunotherapy with
Tregs may compromise general immunity and blunt responses
to other infectious agents remain to be fully assessed.
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Anti-inﬂammatory therapies
Breakthroughs in our understanding of how immune homeo-
stasis is established, maintained or disrupted in the presence
of fungal exposure and/or colonization could be sources of
new therapeutics and drugs targeting speciﬁc inﬂammatory or
metabolic endpoints. In essence, limiting inﬂammation to stim-
ulate a protective immune response to fungi should pave the
way for the rational design of novel immunomodulatory thera-
pies. Below are examples of new therapeutics that are poten-
tially capable of simultaneously activating antifungal resistance
and taming overzealous inﬂammatory host responses.
PTX3
PTX3 is receiving great attention as a potential therapeutic
agent with anti-inﬂammatory properties in aspergillosis.
PTX3 is an opsonin that forms complexes on the conidial
surface of A. fumigatus, thereby amplifying the innate immune
response. Remarkably, PTX3 deﬁciency rendered immuno-
competent mice highly susceptible to A. fumigatus infection
[21], whereas PTX3 administration protected against invasive
aspergillosis in mice with T-cell-depleted allogeneic trans-
plants and potentiated the efﬁcacy of amphotericin B. More
recently, early administration of exogenous PTX3 was shown
to enhance the conidiocidal activity of neutrophils and limit
the inﬂammatory pathology in NADPH oxidase-deﬁcient
mice [22]. Finally, a number of predominantly non-coding
polymorphisms have been identiﬁed in the PTX3 gene that
could be relevant in clinical fungal infections [23].
IDO and tryptophan metabolites
It has been shown that resistance and tolerance are two types
of host defence mechanism to increase ﬁtness in response to
fungi [5]. In experimental fungal infections, both defence mech-
anisms are activated through the delicate equilibrium between
Th1 cells (which provide antifungal resistance mechanisms)
and Tregs, which limit the consequences of the associated
inﬂammatory pathology [24]. IDO and kynurenines pivotally
contribute to this delicate balance by providing the host with
immune mechanisms that are adequate for protection without
necessarily eliminating fungal pathogens or causing an unac-
ceptable level of tissue damage [24]. Through their capacity to
induce Tregs and inhibit Th17, IDO and kynurenines pivotally
contribute to cell lineage decisions in experimental fungal
infections, and have shown an unexpected potential to control
inﬂammation, allergy and Th17-driven inﬂammation in these
infections [24]. In this context, the Th17 pathway, which
downregulates tryptophan catabolism, may instead favour
pathology [25] and serve to explain the seemingly paradoxical
association of chronic inﬂammation with fungal disease. In
experimental CGD, interleukin-17 neutralization increased
fungal clearance, ameliorated inﬂammatory pathology, and
restored protective Th1 antifungal resistance [10]. Perhaps
more importantly, complete cure and reversal of the hyperin-
ﬂammatory CGD phenotype were achieved by administration
of supplemental L-kynurenine, an early amino acid catabolite of
L-tryptophan in the IDO-dependent pathway.
Thymosin a1 (Ta1)
Innate signalling may either activate or limit, via induction of
Tregs, adaptive immunity. This implies that selected PRR
ligands might be useful candidate adjuvants with which to
dampen inﬂammatory responses associated with infections.
Ta1, a naturally occurring thymic peptide, which is approved
in 30 countries for the treatment of a number of viral infec-
tions [26] and as an immune adjuvant, has been found to
promote maturation of and cytokine production by DCs via
TLR signalling [27]. By controlling the balance between the
activity of immunogenic and tolerogenic DCs, Ta1 acted as
an endogenous immune regulator that was capable of induc-
ing protective immunity to A. fumigatus. In effect, Ta1 was
found to induce IDO expression and production of kynure-
nines, thereby imprinting a tolerogenic programme into
inﬂammatory DCs [27]. Thus, instructive immunotherapy
(therapy based on the instruction/education of speciﬁc cell
types) with Ta1 targeting IDO-competent DCs could
allow for balanced control of inﬂammation and tolerance in
aspergillosis.
Targeting inﬂammatory pathways with small interfering
RNAs (siRNAs)
The intranasal administration of siRNAs has opened new
avenues in drug delivery and respiratory therapy [28].
Although the in vivo use of siRNAs has been limited, they
have huge potential as therapeutic agents, given the absence
of adverse immune reactions and systemic access. Adding to
the potential of siRNAs as therapeutic agents in the areas of
cancer and viral infections, a recent study showed the poten-
tial of siRNAs to attenuate inﬂammation in respiratory fungal
infections [29]. In vivo targeting of inﬂammatory (phospho-
inositide 3-kinase/Akt/mTOR) or anti-inﬂammatory (STAT3/
IDO) pathways by intranasally delivered siRNAs modiﬁed
inﬂammation and immunity in aspergillosis. Thus, the screen-
ing of signalling pathways through a systems biology approach
may be exploited for the development of siRNA therapeutics
to attenuate inﬂammation in respiratory fungal infections and
diseases. Ultimately, because immunity is neither simply a set
of discrete signalling pathways activated by pathogens nor a
function of the host, the utilization of systems biology
approaches is useful for the generation of new therapeutics
that target pathogenicity rather than microbial growth, the
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host–pathogen interface rather than the pathogen, and pro-
mote protective immune responses.
Vaccine development
With the exception of a killed spherule vaccine for coccidioido-
mycosis, no fungal vaccine trials have ever been conducted.
However, the level of our understanding of fungal–host interac-
tions has progressed to the point where vaccines against both
primary fungal pathogens and the prevalent opportunistic fungi
are becoming a reality [30]. In this regard, given the plasticity of
the DC system in initiating disparate immune responses to
fungi, vaccine-induced education of T-cells could be regarded
as a promising strategy to reduce the risk of fungal infection.
Genetic Variability and Immunotherapy
Outcome: Towards Personalized
Treatments?
Although the dissection of the complex genetic traits modu-
lating susceptibility to fungal infections is a challenge, the
contribution of host genetics may hold the key to elucidating
genetic markers for fungal infections and diseases occurring
in high-risk patients. The lack of understanding regarding
which patients are at highest risk of developing a life-threat-
ening infection is at present a major deﬁciency, and genetic
markers will probably assist in risk assessment. A number of
studies have investigated the role of genetic variability in
deﬁning individual susceptibility to fungal infections [2,3]. A
single-nucleotide polymorphism in TLR4 was shown to be a
risk factor for chronic aspergillosis in immunocompetent
individuals [31], and later for invasive aspergillosis among
unrelated patients with allogeneic transplants [32]. More
recently, the stop codon polymorphism Y238X in dectin-1
was also found to contribute to increased susceptibility to
aspergillosis in the stem cell transplantation setting; this study
also revealed the distinct contributions of the haematopoietic/
non-haematopoietic cell compartments to the induction of
immune protection against the fungus [33]. Although consider-
able efforts have been made in this direction, there is still the
problem of the limited power of the existing studies. Larger,
well-designed trials, preferably performed in consecutive
patients, are ultimately required to clarify the usefulness of
genetic stratiﬁcation of patients at risk for infection.
Perspectives in Antifungal Immunotherapy
The new discoveries in the ﬁeld of fungal immunology have
offered new grounds for a better comprehension of cells and
immune pathways that are amenable to manipulation in
patients with or at risk of fungal infections (Fig. 1). By inﬂu-
encing immune responses and inﬂammation, single-nucleotide
polymorphisms in genes concerned with immunity may also
affect the outcome of immunotherapeutic interventions.
Therefore, when immunotherapeutic strategies are being
devised, the new conceptual advances in the knowledge of
antifungal immunity should not only be considered, but also
accommodated from an immunogenetic standpoint. Identify-
ing the cellular and molecular bases affected by genetic poly-
morphisms may prove to be very powerful in maximizing the
potential of therapeutic targets and prophylactic strategies
that exert control over the outcome of immune pathways.
Altogether, the genetic screening of at-risk patients may ulti-
mately be used to individualize treatments through the for-
mulation of new targeted and patient-tailored antifungal
immunotherapeutics, probably improving the management
and outcome of fungal infections.
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